1. Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy 
Jean–François Rahier, Sébastien Buche, Laurent Peyrin–Biroulet, Yoram Bouhnik, Bernard Duclos, Edouard Louis, Pavol Papay, Matthieu Allez, Jacques Cosnes, Antoine Cortot, David Laharie, Jean–Marie Reimund, Marc Lémann, Emmanuel Delaporte, Jean– Frédéric Colombel 
Clinical Gastroenterology and Hepatology 
Volume 8, Issue 12, Pages (December 2010)
DOI: /j.cgh
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
(A) Psoriasiform lesions of the scalp (tinea amiantacea form) induced by infliximab. (B) Flexural psoriasiform lesions of the pubic region induced by infliximab. (C) Flexural psoriasiform lesions of axillae folds induced by adalimumab. (D) Palmo-plantar pustulosis induced by adalimumab.
Clinical Gastroenterology and Hepatology 2010 8, DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
Outcomes of psoriasiform lesions and effect of switching the anti–tumor necrosis factor (TNF) therapy.
Clinical Gastroenterology and Hepatology 2010 8, DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
(A) Eczematiform lesions of the face induced by adalimumab. (B) Nummular eczematiform lesion of lower left member induced by adalimumab.
Clinical Gastroenterology and Hepatology 2010 8, DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

5. Figure 4
Outcomes of eczematiform lesions and effect of switching the anti–tumor necrosis factor (TNF) therapy.
Clinical Gastroenterology and Hepatology 2010 8, DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions